Appears On
Episode Appearances
BioSpace · May 13, 2026
Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay
“Highest paid pharma CEO in 2025 at $36.7M; face of GLP-1 market; conducting media victory lap”
FDA Commissioner leadership transition and removalRegulatory uncertainty and HHS agency turnoverCommissioner's National Priority Review voucher program
View Analysis